TABLE 1.
Study cohort characteristics (permanent sample of beneficiaries 2009–2016—n = 106 437)
| ≥50 years at inclusion n = 106 437 | ≥75 years at inclusion n = 21 852 | ||
|---|---|---|---|
| % a | % a | ||
| Sex | Women | 52.0 | 59.9 |
| Age at inclusion | 50–64 | 57.4 | |
| 65–74 | 22.1 | ||
| 75–84 | 15.2 | 73.9 | |
| ≥85 | 5.4 | 26.1 | |
| Death during follow‐up | 12.2 | 35.0 | |
| Mean duration of follow‐up (y), mean (SD) | 7.3 (1.8) | 6.0 (2.6) | |
| At least 1 benzodiazepine dispensed during follow‐up | 36.3 | 24.2 | |
| At least 1 antidepressant dispensed during follow‐up | 21.7 | 27.4 | |
| At least 1 antipsychotic dispensed during follow‐up | 4.8 | 9.2 | |
| At least 1 antiepileptic dispensed during follow‐up | 15.1 | 16.3 | |
| At least 1 oral antidiabetic dispensed during follow‐up | 17.7 | 19.4 | |
| At least 1 antihypertensive agent dispensed during follow‐up | 59.1 | 78.3 | |
| At least 1 drug used in alcohol dependence dispensed during follow‐up | 0.8 | 0.1 | |
| Parkinson's disease/dementia condition during follow‐up | 5.3 | 18.5 | |
| Osteoporosis during follow‐up | 2.4 | 40 | |
| Age‐related macular degeneration during follow‐up | 1.2 | 2.6 | |
| Diabetes during follow‐up | 16.5 | 20.3 | |
| Epilepsy during follow‐up | 1.2 | 1.7 | |
| Psychiatric condition during follow‐up | 2.2 | 1.9 | |
| Cardiovascular diseases during follow‐up | 31.1 | 54.8 | |
| Somatic multimorbidity score during follow‐up, mean (SD) | 0.4 (0.3) | 0.5 (0.3) |
a
Unless otherwise stated.
SD: standard deviation.